The Relationship of Anti-Mullerian Hormone in Polycystic Ovary Syndrome Patients With Different Subgroups

Ran, Yu; Li, Cong; Yi, Qiang; Qiao, Hong; Yang, Qing; Ye, Yanli

doi:10.21203/rs.3.rs-133452/v1

Cited by 2 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Androgens increase GC FSH receptors (FSHR), and increased FSH action stimulates AMH expression from growing follicles in PCOS 65,67 . Higher AMH levels were observed in anovulatory and hyper‐androgenic women with PCOS compared with normo‐androgenic women 67,68 . In women, AMH levels better predicted oligo/amenorrhoea than AFC 69 .…”

Section: Introductionmentioning

confidence: 99%

Treatments targeting neuroendocrine dysfunction in polycystic ovary syndrome (PCOS)

Garg

Patel

Abbara

et al. 2022

Clinical Endocrinology

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age and is the leading cause of anovulatory subfertility.Increased gonadotrophin releasing hormone (GnRH) pulsatility in the hypothalamus results in preferential luteinizing hormone (LH) secretion from the pituitary gland, leading to ovarian hyperandrogenism and oligo/anovulation.The resultant hyperandrogenism reduces negative feedback from sex steroids such as oestradiol and progesterone to the hypothalamus, and thus perpetuates the increase in GnRH pulsatility. GnRH neurons do not have receptors for oestrogen, progesterone, or androgens, and thus the disrupted feedback is hypothesized to occur via upstream neurons. Likely candidates for these upstream regulators of GnRH neuronal pulsatility are Kisspeptin, Neurokinin B (NKB), and Dynorphin neurons (termed KNDy neurons). Growing insight into the neuroendocrine dysfunction underpinning the heightened GnRH pulsatility seen in PCOS has led to research on the use of pharmaceutical agents that specifically target the activity of these KNDy neurons to attenuate symptoms of PCOS. This review aims to highlight the neuroendocrine abnormalities that lead to increased GnRH pulsatility in PCOS, and outline data on recent therapeutic advancements that could potentially be used to treat PCOS. Emerging evidence has investigated the use of neurokinin 3 receptor (NK3R) antagonists as a method of reducing GnRH pulsatility and alleviating features of PCOS such as hyperandrogenism. We also consider other potential mechanisms by which increased GnRH pulsatility is controlled, which could form the basis of future avenues of research.

show abstract

Section: Introductionmentioning

confidence: 99%

Treatments targeting neuroendocrine dysfunction in polycystic ovary syndrome (PCOS)

Garg

Patel

Abbara

et al. 2022

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…In our investigation, we discovered that the patient's age might predict AMH levels and a substantial negative connection, comparable to Ran et al's (2021) results, who found similar alterations in a healthy control group. 24 However, another research found comparable alterations in healthy young females but no link in PCOS people. 25 We also discovered a link between blood pressure and AMH.…”

Section: Discussionmentioning

confidence: 97%

Role of antimullarian hormone in the diagnosis of sonographically inconclusive polycystic ovary syndrome

Banu

Morshed²,

Tuqan

et al. 2023

Bangabandhu Sheikh Mujib Medical University Journal

View full text Add to dashboard Cite

Antimullarian hormone (AMH) is found to be a vital tool for the diagnosis of polycystic ovary syndrome (PCOS). AMH may help in the diagnosis of sonographically inconclusive cases of PCOS. This study measured the AMH level in PCOS to assess its impacts on the diagnosis of the syndrome. This cross-sectional study included 160 newly diagnosed females with PCOS who were diagnosed using a modified revised Rotterdam criteria. Fasting blood was collected to measure AMH by enzyme-linked immunosorbent assay and other hormones [total testosterone, luteinizing hormone and follicle-stimulating hormone] were measured by chemiluminescent microparticle immunoassay. Ovarian USG was done in the follicular phase of the menstrual cycle. Serum AMH≥ 3.5 ng/mL and ovarian volume >10 mL was considered as a combined marker of polycystic ovary (PCO). USG-PCO criteria could detect 84.38% PCO, whereas AMH-PCO criteria 67.5%. There was a lack of agreement between USG-PCO and AMH-PCO criteria [κ=-0.004] in PCOS. AMH-PCO criteria identified 68% of PCO patients undiagnosed by USG-PCO criteria [17/25]. Age [β=-0.172, p=0.040], systolic [β =-0.213, p=0.037] and diastolic blood pressure [β=0.301, p=0.004] had significant predictive associations with AMH by linear regression. AMH had a fair discriminating index for combined-PCO [AUC=0.824] in PCOS patients. In conclusion, AMH assessment can help detect PCOS patients who are inconclusively diagnosed by USG-PCO criteria. BSMMU J 2022; 15(2): 65-69

show abstract

The Relationship of Anti-Mullerian Hormone in Polycystic Ovary Syndrome Patients With Different Subgroups

Cited by 2 publications

References 30 publications

Treatments targeting neuroendocrine dysfunction in polycystic ovary syndrome (PCOS)

Treatments targeting neuroendocrine dysfunction in polycystic ovary syndrome (PCOS)

Role of antimullarian hormone in the diagnosis of sonographically inconclusive polycystic ovary syndrome

Contact Info

Product

Resources

About